|
시장보고서
상품코드
1563125
세계의 연속 혈당 측정 시스템 시장 : 제품별, 용도별, 최종사용자별, 지역별 예측(-2032년)Global Continuous Glucose Monitoring Systems Market Research Report Information by Product, By Application, By End User, by Region Forecast till 2032 |
||||||
연속 혈당 측정 시스템 시장 규모는 2023년 88억 달러, 2024년 100억 달러에서 예측 기간 동안 12.34%의 복합 연간 성장률(CAGR)로 성장을 지속하여 2032년에는 258억 달러 규모로 성장할 것으로 예측됩니다.
연속 혈당 측정 시스템 시장 확대를 촉진하는 주목할만한 요인 중 하나는 세계의 당뇨병 유병률의 상승입니다. 세계의 이환 환자의 상당한 증가로 당뇨병은 이제 유행의 비율에 도달했습니다. The International Diabetes Federation(IDF)은 2021년에는 세계에서 5억 3,700만명이 당뇨병을 앓고 있으며, 이 숫자는 2030년에는 6억 4,300만명으로 증가할 것으로 예측했습니다. 마찬가지로 IDF는 2021년 인구의 11.6%에 해당하는 3,840만 명의 미국인이 당뇨병을 앓고 있다고 추정합니다. 약 30만 4,000명의 어린이와 십대를 포함한 약 200만명의 미국인이 1형 당뇨병입니다. 당뇨병 이환율 상승의 원인으로는 인구의 고령화, 식습관의 혼란, 불활발한 라이프 스타일 등을 들 수 있습니다. 당뇨병 인구가 증가함에 따라 효율적인 당뇨병 관리 솔루션의 필요성이 커지고 있습니다.
지역별 인사이트력
북미 시장은 가장 큰 점유율을 보여줍니다. 견고한 기술 인프라가 그 배경에 있으며, 확립된 규제 체제가 시장을 견인한다고 가정합니다.
유럽은 당뇨병 유병률 상승과 CGM 기술 개발로 2위 시장 점유율을 차지하고 있습니다.
아시아태평양은 2023년부터 2032년까지 주목 비율로 성장할 것으로 예측됩니다. 이것은 이 지역에서 당뇨병 유병률이 증가하고 당뇨병 관리에 대한 의식이 증가한 결과입니다.
이 보고서는 세계의 연속 혈당 측정 시스템 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추이, 예측, 각종 구분, 지역별 분석, 경쟁 환경, 주요 기업 프로파일 등을 정리했습니다.
목차
제1장 주요 요약
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
- 성장 촉진요인
- 당뇨병의 이환율 증가
- 연속 혈당 측정 시스템과 환자 교육의 이점에 대한 개인 의식 증가
- 고령화 인구 증가
- 억제요인
- 연속 혈당 측정 시스템의 고비용성
- 기회
- 기술의 진보와 혁신의 진전
제5장 시장 요인 분석
- 밸류체인 분석
- Porter's Five Forces 분석
- COVID-19가 세계의 연속 혈당 측정 시스템 시장에 미치는 영향
제6장 세계의 연속 혈당 측정 시스템 시장 : 제품별
- 개요
- 센서
- 송신기,수신기
제7장 세계의 연속 혈당 측정 시스템 시장 : 용도별
- 개요
- 2형 당뇨병
- 1형 당뇨병
- 비당뇨병 환자
- 체중 감량
- 다이어트 관리
- 건강,웰빙
제8장 세계의 연속 혈당 측정 시스템 시장 : 최종 사용자별
- 개요
- 병원 및 클리닉
- 홈케어
- 기타
제9장 세계의 연속 혈당 측정 시스템 시장 : 지역별
- 세계의
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제10장 경쟁 구도
- 시장 점유율 분석
- 경쟁 대시보드
- 공개 기업의 주식 개요
- 비교 분석 : 주요 기업의 재무 동향
- 주요 전개와 성장 전략
제11장 기업 프로파일
- DEXCOM, INC
- A. MENARINI DIAGNOSTICS SRL
- SENSEONICS
- MEDTRUM TECHNOLOGIES INC.
- NEMAURA MEDICAL INC.
- ULTRAHUMAN HEALTHCARE PVT LTD
- MEDTRONIC
- ONE DROP
- ABBOTT LABORATORIES, INC.
- SINOCARE
- NUTRISENSE
- SUPERSAPIENS
- SIGNOS INC.
- LEVELS
- VERI
- LUMEN
- JANUARY.AI
제12장 데이터 인용
BJH 24.10.08Global Continuous Glucose Monitoring Systems Market Research Report Information by Product (Sensors, And Transmitter and Receivers), By Application (Type 2, Type 1, Non-diabetic Patients), By End User (Hospitals & Clinics, Homecare Settings, And Others), by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032
Market Outlook
USD 8.8 billion in continuous glucose monitoring systems market value in 2023 With a compound annual growth rate (CAGR) of 12.34% for the forecast period (2024 - 2032), the market for Continuous Glucose Monitoring Systems is expected to rise from USD 10.0 Billion in 2024 to USD 25.8 billion by 2032.
One very notable factor driving the expansion of the Continuous Glucose Monitoring Systems Market is the rising global diabetes prevalence. With an amazing global increase in affected individuals, diabetes now reaches pandemic proportions. The International Diabetes Federation (IDF) estimates that 537 million people globally will be living with diabetes in 2021 and that figure is predicted to rise to 643 million by 2030. Likewise, the American Diabetes Association estimates that in 2021 diabetes will afflict 38.4 million Americans, or 11.6% of the population. About 2.0 million Americans, including some 304,000 children and teenagers, have type 1 diabetes. Among the several causes of the rising diabetes incidence include aging population, poor eating habits, and inactive lifestyles. The need of efficient diabetes care solutions gets more urgent as the diabetic population keeps rising.
Insights about Market Segments
Based on product, the segmentation of the Continuous Glucose Monitoring Systems Market divides sensors and transmitter and receivers.
Application that comprises type 2 diabetes, type 1 diabetes, and non-diabetic patients forms the basis of the market segmentation.
End users ranging from hospitals and clinics to homecare environments and others form the basis of the market segmentation.
Regional Insights
The report groups the market by Region: North America, Europe, Asia-Pacific, and the Rest of the World. America North-West With a market share of the highest 2023 constant glucose monitoring systems The strong technological infrastructure is the reason behind this; so, it is envisaged that the market would be driven by a well-established regulatory framework.
Thanks to rising diabetes prevalence in Europe and developments in CGM technology, Europe Continuous Glucose Monitoring Systems market holds second-largest market share. Furthermore, the Rest of Europe Continuous Glucose Monitoring Systems market is predicted to fastest-growing market in the European area while France Continuous Glucose Monitoring Systems market was ascribed to hold the highest market share.
From 2023 to 2032, the Asia-Pacific Continuous Glucose Monitoring Systems market is predicted to expand at a noteworthy proportion. This is a result of growing diabetes prevalence in the area and growing consciousness of diabetes control. Furthermore projected to have the biggest market share is China Continuous Glucose Monitoring Systems market; India Market for Continuous Glucose Monitoring Systems is predicted to develop fastest among Asia-Pacific countries.
The Middle East and Africa plus Latin America comprise the Rest of the World. Rising diabetes prevalence along with growing awareness of advanced glucose monitoring systems would probably cause the market for Continuous Glucose Monitoring Systems in the above stated areas to rise.
Leading Players
Key Companies in the Continuous Glucose Monitoring Systems Market are Dexcom, Inc. (US), Menarini Diagnostics SRL (Italy), Sensonics (US), Medtrum Technologies Inc. (China), Nemaura Medical Inc. (US), Ultrahuman Healthcare Pvt LTD (India), Medtronic (Ireland), One Drop (US), Abbott Laboratories, Inc. (US), Sinocare (China).
TABLE OF CONTENTS
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
- 3.1 OVERVIEW
- 3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
- 3.3 PURCHASED DATABASE:
- 3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
- 3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
- 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
- 3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TECHNIQUE
- 3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
- 3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
- 4.1 INTRODUCTION
- 4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF DIABETES
- 4.2.2 RISING AWARENESS AMONG INDIVIDUALS ABOUT THE BENEFITS OF CONTINUOUS GLUCOSE MONITORING AND PATIENT EDUCATION
- 4.2.3 INCREASING GERIATRIC POPULATION
- 4.3 RESTRAINTS
- 4.3.1 HIGH COST OF CONTINUOUS GLUCOSE MONITORING SYSTEMS
- 4.4 OPPORTUNITY
- 4.4.1 GROWING TECHNOLOGICAL ADVANCEMENTS AND INNOVATION
5 MARKET FACTOR ANALYSIS
- 5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION AND SALES
- 5.1.4 POST-SALES MONITORING
- 5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
- 5.3 IMPACT OF COVID-19 ON THE GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET
- 5.3.1 OVERVIEW
6 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY PRODUCT
- 6.1 OVERVIEW
- 6.2 SENSORS
- 6.3 TRANSMITTER & RECEIVERS
7 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY APPLICATION
- 7.1 OVERVIEW
- 7.2 TYPE 2 DIABETES
- 7.3 TYPE 1 DIABETES
- 7.4 NON-DIABETIC PATIENTS
- 7.4.1 WEIGHT LOSS
- 7.4.2 DIET MANAGEMENT
- 7.4.3 HEALTH & WELLNESS
8 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER
- 8.1 OVERVIEW
- 8.2 HOSPITALS & CLINICS
- 8.3 HOMECARE SETTINGS
- 8.4 OTHERS
9 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION
- 9.1 GLOBAL
- 9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
- 9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
- 9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 INDIA
- 9.4.3 JAPAN
- 9.4.4 SOUTH KOREA
- 9.4.5 AUSTRALIA
- 9.4.6 REST OF ASIA-PACIFIC
- 9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST & AFRICA
- 9.5.2 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
- 10.1 INTRODUCTION
- 10.2 MARKET SHARE ANALYSIS,
- 10.3 COMPETITOR DASHBOARD
- 10.4 PUBLIC PLAYERS STOCK SUMMARY
- 10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
- 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
- 10.6.2 AGREEMENT
- 10.6.3 PARTNERSHIP
- 10.6.4 COLLABORATION
11 COMPANY PROFILES
- 11.1 DEXCOM, INC
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
- 11.2 A. MENARINI DIAGNOSTICS SRL
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 KEY STRATEGIES
- 11.3 SENSEONICS
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 KEY STRATEGIES
- 11.4 MEDTRUM TECHNOLOGIES INC.
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 KEY STRATEGIES
- 11.5 NEMAURA MEDICAL INC.
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 SWOT ANALYSIS
- 11.5.6 KEY STRATEGIES
- 11.6 ULTRAHUMAN HEALTHCARE PVT LTD
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 KEY STRATEGIES
- 11.7 MEDTRONIC
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
- 11.8 ONE DROP
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGIES
- 11.9 ABBOTT LABORATORIES, INC.
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 SWOT ANALYSIS
- 11.9.6 KEY STRATEGIES
- 11.10 SINOCARE
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES
- 11.11 NUTRISENSE
- 11.11.1 COMPANY OVERVIEW
- 11.11.2 FINANCIAL OVERVIEW
- 11.11.3 PRODUCTS OFFERED
- 11.11.4 KEY DEVELOPMENTS
- 11.11.5 KEY STRATEGIES
- 11.12 SUPERSAPIENS
- 11.12.1 COMPANY OVERVIEW
- 11.12.2 FINANCIAL OVERVIEW
- 11.12.3 PRODUCTS OFFERED
- 11.12.4 KEY DEVELOPMENTS
- 11.12.5 KEY STRATEGIES
- 11.13 SIGNOS INC.
- 11.13.1 COMPANY OVERVIEW
- 11.13.2 FINANCIAL OVERVIEW
- 11.13.3 PRODUCTS OFFERED
- 11.13.4 KEY DEVELOPMENTS
- 11.13.5 KEY STRATEGIES
- 11.14 LEVELS
- 11.14.1 COMPANY OVERVIEW
- 11.14.2 FINANCIAL OVERVIEW
- 11.14.3 PRODUCTS OFFERED
- 11.14.4 KEY DEVELOPMENTS
- 11.14.5 KEY STRATEGIES
- 11.15 VERI
- 11.15.1 COMPANY OVERVIEW
- 11.15.2 FINANCIAL OVERVIEW
- 11.15.3 PRODUCTS OFFERED
- 11.15.4 KEY DEVELOPMENTS
- 11.15.5 KEY STRATEGIES
- 11.16 LUMEN
- 11.16.1 COMPANY OVERVIEW
- 11.16.2 FINANCIAL OVERVIEW
- 11.16.3 PRODUCTS OFFERED
- 11.16.4 KEY DEVELOPMENTS
- 11.16.5 KEY STRATEGIES
- 11.17 JANUARY.AI
- 11.17.1 COMPANY OVERVIEW
- 11.17.2 FINANCIAL OVERVIEW
- 11.17.3 PRODUCTS OFFERED
- 11.17.4 KEY DEVELOPMENTS
- 11.17.5 KEY STRATEGIES
